Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
äŒæ¥ã³ãŒãDERM
äŒç€ŸåJourney Medical Corp
äžå Žæ¥Nov 12, 2021
æé«çµå¶è²¬ä»»è
ãCEOãMaraoui (Claude)
åŸæ¥å¡æ°41
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Nov 12
æ¬ç€Ÿæåšå°9237 E Via De Ventura Blvd., Suite 105
éœåžSCOTTSDALE
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·85258
é»è©±çªå·14804346670
ãŠã§ããµã€ãhttps://journeymedicalcorp.com/
äŒæ¥ã³ãŒãDERM
äžå Žæ¥Nov 12, 2021
æé«çµå¶è²¬ä»»è
ãCEOãMaraoui (Claude)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã